168 completed, 48 terminated, 14 unknown, 12 withdrawn. 91 Phase 3, 89 Phase 2, 34 Phase 4, 22 Phase 1, 20 Not applicable.
Follow Epoetin Alfa: new trials by email Literature Review of Epoetin Alfa trials Research Report on Epoetin Alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 270 | 2026-12-18 | 2026-09-22 |
| Pharmacokinetics, Pharmacodynamics, and Safety of NANOKINE Compared With Eprex 4000 U in Healthy Volunteers Erythropoietin alfa - Pharmacokinetics and Pharmacodynamics in Healthy Volunteers | Phase 1 | Not yet recruiting | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 44 | 2026-09-01 | 2026-08-03 |
| Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis Epoetin Alfa (drug), Daprodustat - Chronic Kidney Disease (Stages 3b-5), Anemia Associated With Chronic Kidney Disease | Not applicable | Not yet recruiting | Services Hospital, Lahore | 60 | 2026-09-01 | 2026-08-10 |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions Elritercept, Epoetin Alfa - Myelodysplastic Syndrome, Anemia | Phase 3 | Recruiting | Takeda | 300 | 2026-05-21 | 2026-10-19 |
| EVR and EPO for Liver Transplant Tolerance Everolimus, Epoetin alfa - Liver Transplant | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-01-21 | 2026-04-06 |
| Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration., Active comparator: European Union licenced epoetin alfa - Anemia of Chronic Kidney Disease | Phase 3 | Not yet recruiting | Megalabs | 280 | 2025-07-01 | 2024-08-19 |
| A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Luspatercept, Epoetin Alfa - Myelodysplastic Syndromes (MDS) | Withdrawn | Bristol-Myers Squibb | 2024-11-30 | 2024-10-09 | ||
| Vafseo Outcomes In-Center Experience Vadadustat, Erythropoiesis Stimulating Agent - Anemia of Chronic Kidney Disease | Phase 3 | Active not recruiting | USRC Kidney Research | 2200 | 2024-11-20 | 2026-03-10 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-29 |
| ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions Luspatercept, Epoetin Alfa - Myelodysplastic Syndromes | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 402 | 2023-10-24 | 2026-06-30 |
| A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars - Renal Anemia | Phase 2 | Completed | Kind Pharmaceuticals LLC | 175 | 2023-05-03 | 2024-06-28 |
| Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients HIF-PHI, Epoetin Alfa - Anemia in Incident Dialysis Patients | Phase 4 | Unknown | Second Xiangya Hospital of Central South University | 400 | 2022-10-20 | 2021-05-25 |
| Pharmacological Countermeasures for High Altitude Acetazolamide, Erythropoietin - Hypobaric Hypoxia | Phase 4 | Active not recruiting | United States Army Research Institute of Environmental Medicine | 18 | 2022-05-27 | 2025-03-26 |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA Luspatercept Injection [Reblozyl], Eprex - MDS, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Groupe Francophone des Myelodysplasies | 150 | 2022-05-18 | 2026-09-29 |
| A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002 Erythropoietin alpha - Natural Blood and Blood Product Toxicity | Phase 1 / Phase 2 | Completed | Globe Biotech Limited | 42 | 2021-10-16 | 2022-10-20 |
| Impact of Erythropoietin on Hematological Adaptations and Physical Performance Epoetin Alfa - Exercise-Induced Anemia, Physical Performance | Phase 4 | Completed | United States Army Research Institute of Environmental Medicine | 8 | 2021-09-01 | 2025-04-18 |
| ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients Epoetin Alfa 40000 UNT/ML, Sodium Chloride 0.9% - Trauma, Traumatic Injury | Phase 3 | Recruiting | Australian and New Zealand Intensive Care Research Centre | 2500 | 2020-11-09 | 2025-07-16 |
| Desidustat in the Treatment of Anemia in CKD on Dialysis Patients Desidustat Oral Tablet, Epoetin Alfa - Chronic Kidney Disease Stage 5 on Dialysis | Phase 3 | Completed | Zydus Lifesciences Limited | 392 | 2020-01-04 | 2021-11-24 |
| CD71 in Dried Blood Spots in Healthy Males EPOGEN® (epoetin alfa), Normal Saline - Healthy Athletes | Early Phase 1 | Completed | Sports Medicine Research and Testing Laboratory | 24 | 2019-07-15 | 2021-03-17 |
| Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia Iron sucrose, Epoetin Alfa, Placebo - Anemia, Iron Deficiency, Anemia of Chronic Disease | Phase 2 | Terminated | Unity Health Toronto | 4 | 2019-07-01 | 2021-06-18 |
Showing 20 of 257. Sign in to see all of them.
Anemia (162) · Renal Insufficiency, Chronic (36) · Neoplasms (27) · Kidney Failure, Chronic (23) · Acquired Immunodeficiency Syndrome (16) · Myelodysplastic Syndromes (16) · HIV Infections (12) · Leukemia (12) · Multiple Myeloma (11) · Cytopenia (10) · Lymphoma (9) · Neoplasms, Plasma Cell (8) · Breast Neoplasms (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Non-Hodgkin (7)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (58) · Hoffmann-La Roche (10) · Ortho Biotech Products, L.P. (10) · Amgen (8) · Azidus Brasil (6) · Ortho Pharmaceuticals (6) · Janssen-Cilag B.V. (5) · Kyntra Bio (5) · Sandoz (5) · Janssen-Ortho Inc., Canada (4) · M.D. Anderson Cancer Center (4) · Affymax (3) · Akebia Therapeutics (3) · Australian and New Zealand Intensive Care Research Centre (3) · Jonsson Comprehensive Cancer Center (3)
United States (99) · Germany (19) · France (17) · Italy (17) · Canada (15) · Poland (14) · Spain (14) · Brazil (13) · United Kingdom (13) · Australia (12) · Netherlands (11) · Russia (11) · Thailand (10) · Belgium (9) · Puerto Rico (9)
John A. Glaspy, MD, MPH (3) · Vice President, Clinical Development (3) · Kamilla W. Miskowiak, Prof. (2) · Michael D Hill, MD (2) · Robin K Ohls, MD (2)
PMID 36791280, PMID 36005278, PMID 38363466, PMID 39301879, PMID 36749544, PMID 16710026, PMID 23343061, PMID 23343062, PMID 26452709, PMID 26965694, PMID 32734207, PMID 15901766, PMID 15953714, PMID 16087945, PMID 16114787, PMID 16177289, PMID 16253719, PMID 16505427, PMID 16553139, PMID 16782926, PMID 16834839, PMID 16877725, PMID 16977654, PMID 17108343, PMID 17312332, PMID 17400086, PMID 17541653, PMID 17699416, PMID 17716826, PMID 17804841, PMID 17950856, PMID 18284320, PMID 18343652, PMID 18400964, PMID 19170225, PMID 19808215, PMID 19927096, PMID 20077249, PMID 20461765, PMID 20802250, PMID 20942940, PMID 21095264, PMID 21558517, PMID 21675055, PMID 21884028, PMID 22732334, PMID 22745272, PMID 23008465, PMID 23033926, PMID 23102686
2016 (3), 2009 (2), 2005 (1), 2008 (1), 2025 (1), M01RR000997 (1), P01HL046925 (1), P30CA015083 (1), P30CA043703 (1), R01AG027518 (1), R01NR008937 (1), R21HD055501 (1), U01NS032228 (1), U10CA021115 (1), U10CA027469 (1)